Abstract 13854: Comparative Efficacy and Safety of Aldosterone Synthase Inhibitors versus Mineralocorticoid Receptor Antagonists for Resistant Hypertension: A Systematic Review and Network Meta-Analysis
Abstract
Introduction: Resistant hypertension often persists despite multidrug therapy, driven by unopposed aldosterone activity. In May 2026, the FDA approved baxdrostat, a first-in-class aldosterone synthase inhibitor. Other agents include mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone. This network meta-analysis compares their efficacy and safety. Methods: We searched major databases for rcts comparing ASIs (baxdrostat, lorundrostat) or MRAs (spironolactone, eplerenone, finerenone) to placebo or each other in resistant hypertension. Primary outcome: change in systolic blood pressure. A Bayesian network meta-analysis was performed using the R meta package. Risk of bias was assessed using ROBS 2.0. Results: A total of 12 RCTs (N=4,267) were included; 58% male, 42% female. Treatment arms: baxdrostat 2 mg (n=393), baxdrostat 1 mg (n=395), placebo (n=397), spironolactone (n=230), eplerenone (n=78), finerenone (n=624), lorundrostat 50 mg (n=542), esaxerenone (n=260). For SBP reduction, baxdrostat 2 mg showed -9.8 mmHg (95% CI -12.6 to -7.0) with highest SUCRA (77%), followed by spironolactone (69%; -20.1 mmHg, 95% CI -31.2 to -9.1) and eplerenone (58%; -8.1 mmHg, 95% CI -8.2 to -8.0). For DBP reduction, spironolactone ranked highest (SUCRA 71%; -5.7 mmHg, 95% CI -8.1 to -3.3), baxdrostat 2 mg achieved -3.9 mmHg (95% CI -5.7 to -2.0). For hyperkalemia (lower SUCRA better), finerenone ranked best (0.95), baxdrostat second (0.81). Hyperkalemia (>6.0 mEq/L) incidence: baxdrostat 2 mg 3.0%, spironolactone 9.6% (95% CI 1.6-40.6). No drug-related deaths occurred. Conclusion: Baxdrostat, a first-in-class aldosterone synthase inhibitor, demonstrates comparable blood pressure reduction to spironolactone in resistant hypertension but with a significantly lower risk of hyperkalemia. It represents a promising new add-on therapy, particularly for patients intolerant to or at high risk from mineralocorticoid receptor antagonists. Further long-term cardiovascular outcome trials are warranted. Risk of bias was low.